CN115697314A - 安非他酮和右美沙芬组合用于治疗神经病症的用途 - Google Patents

安非他酮和右美沙芬组合用于治疗神经病症的用途 Download PDF

Info

Publication number
CN115697314A
CN115697314A CN202180038675.3A CN202180038675A CN115697314A CN 115697314 A CN115697314 A CN 115697314A CN 202180038675 A CN202180038675 A CN 202180038675A CN 115697314 A CN115697314 A CN 115697314A
Authority
CN
China
Prior art keywords
dextromethorphan
bupropion
week
hydroxybupropion
beginning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038675.3A
Other languages
English (en)
Chinese (zh)
Inventor
赫里奥特·塔布提奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antecip Bioventures II LLC
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/894,713 external-priority patent/US10898453B2/en
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Publication of CN115697314A publication Critical patent/CN115697314A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180038675.3A 2020-03-30 2021-03-29 安非他酮和右美沙芬组合用于治疗神经病症的用途 Pending CN115697314A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063002132P 2020-03-30 2020-03-30
US63/002,132 2020-03-30
US202063016178P 2020-04-27 2020-04-27
US63/016,178 2020-04-27
US202063032517P 2020-05-29 2020-05-29
US63/032,517 2020-05-29
US202063032567P 2020-05-30 2020-05-30
US63/032,567 2020-05-30
US16/894,713 US10898453B2 (en) 2013-11-05 2020-06-05 Bupropion as a modulator of drug activity
US16/894,713 2020-06-05
PCT/US2021/024718 WO2021202419A1 (en) 2020-03-30 2021-03-29 Use of bupropion and dextromethorphan combinations for treating neurological disorders

Publications (1)

Publication Number Publication Date
CN115697314A true CN115697314A (zh) 2023-02-03

Family

ID=77930161

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038675.3A Pending CN115697314A (zh) 2020-03-30 2021-03-29 安非他酮和右美沙芬组合用于治疗神经病症的用途

Country Status (6)

Country Link
EP (1) EP4125837A4 (https=)
JP (2) JP7637150B2 (https=)
KR (1) KR20220161414A (https=)
CN (1) CN115697314A (https=)
CA (1) CA3179048A1 (https=)
WO (1) WO2021202419A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
EP4255433A4 (en) 2020-12-01 2024-05-29 Antecip Bioventures II LLC BUPROPION AND DEXTROMETHORPHAN FOR REDUCING THE RISK OF SUICIDE IN DEPRESSED PATIENTS
EP4373480A4 (en) * 2021-07-21 2025-05-28 Antecip Bioventures II LLC TREATMENT OF DEPRESSION
KR20250011185A (ko) * 2022-05-17 2025-01-21 안테씨프 바이오벤쳐스 투 엘엘씨 우울증의 치료
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) * 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
WO2024118570A1 (en) * 2022-11-28 2024-06-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9763932B2 (en) * 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10898453B2 (en) * 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) * 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11273134B2 (en) * 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
MY179696A (en) * 2013-11-05 2020-11-11 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan
US11007189B2 (en) * 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity

Also Published As

Publication number Publication date
KR20220161414A (ko) 2022-12-06
EP4125837A4 (en) 2024-03-20
JP7637150B2 (ja) 2025-02-27
JP2025032232A (ja) 2025-03-11
EP4125837A1 (en) 2023-02-08
JP2023519965A (ja) 2023-05-15
CA3179048A1 (en) 2021-10-07
WO2021202419A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20250032432A1 (en) Bupropion as a modulator of drug activity
US11571399B2 (en) Bupropion as a modulator of drug activity
US11253491B2 (en) Bupropion as a modulator of drug activity
US11147808B2 (en) Method of decreasing the fluctuation index of dextromethorphan
US10966941B2 (en) Bupropion as a modulator of drug activity
US11344544B2 (en) Bupropion as a modulator of drug activity
US11191739B2 (en) Bupropion as a modulator of drug activity
US11123344B2 (en) Bupropion as a modulator of drug activity
US11065248B2 (en) Bupropion as a modulator of drug activity
US11298351B2 (en) Bupropion as a modulator of drug activity
US11234946B2 (en) Bupropion as a modulator of drug activity
US11058648B2 (en) Bupropion as a modulator of drug activity
US11207281B2 (en) Bupropion as a modulator of drug activity
US11213521B2 (en) Bupropion as a modulator of drug activity
US11123343B2 (en) Bupropion as a modulator of drug activity
US10980800B2 (en) Bupropion as a modulator of drug activity
US10898453B2 (en) Bupropion as a modulator of drug activity
US10933034B2 (en) Bupropion as a modulator of drug activity
US20230277478A1 (en) Bupropion as a modulator of drug activity
CN115697314A (zh) 安非他酮和右美沙芬组合用于治疗神经病症的用途
CN112437659B (zh) 用于治疗抑郁症的右美沙芬和安非他酮的组合
US20210220348A1 (en) Bupropion as a modulator of drug activity
US20210186955A1 (en) Bupropion as a modulator of drug activity
US20210069125A1 (en) Bupropion as a modulator of drug activity
US20220031691A9 (en) Bupropion as a modulator of drug activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080675

Country of ref document: HK